Type: Oral
Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Risk Adapted Approaches to Reduce Transplant Related Toxicities
Hematology Disease Topics & Pathways:
Viral, Diseases, Infectious Diseases, Adverse Events
Methods: We examined the clinical manifestations, risk factors, and prognosis of 136 adult patients infected with B19 at our institution from 2017 to 2023. A control group of 408 patients without B19 infection was selected using propensity score matching. Single cell full-length RNA sequence (scFAST-seq) of four B19-infected patients and four B19-negative patients after HSCT were adopted to profile B19-infected cell spectrum and functional characteristics. Polymerase chain reaction (PCR) were performed to validate scFAST-seq results.
Results: Our study revealed a 2.6% incidence of B19 DNA viremia after allo-HSCT, with a median onset of 94 days post-transplant. Severe anemia, granulocytopenia, and thrombocytopenia were observed in 69.1%, 80.9%, and 96.3% of B19-positive patients, respectively. Persistent B19 infection, defined as B19 DNAemia lasting for 28 days or more occurred in 48 patients, often accompanied by severe pancytopenia (97.9%) and organ complications (54.1%). Importantly, B19 infection significantly correlated with poorer transplant outcomes, evidenced by higher non-relapse mortality and lower overall survival at 1, 3, and 5 years compared to the control group. Based on scFAST-seq data, we found that in adition to erythroid-lineage cells, which are well-known targets of B19, this virus could infect a broad spectrum of the hematopoietic system, including giant bone marrow myeloid and lymphoid-lineage cells, and even hematopoietic stem cells (HSCs). Interestingly, the scFAST-seq data showed a dramatic decrease in hematopoietic stem cells in patients infected with B19, which suggest that B19 may impair the survival of HSCs, potentially leading to pancytopenia. Moreover, B19-infected HSCs exhibited a higher expression levels of differentiation pathways toward downstream lineages, which may suggest that B19 disease originates from the infected HSCs.
Conclusion: This study provides a comprehensive clinical overview of B19 infection following HSCT and indicates poorer transplant outcomes in patients with B19 infection. Importantly, our findings suggest that B19 can infect a broad spectrum of the hematopoietic system post-HSCT, potentially originating from infected hematopoietic stem cells in patients with persistent B19 infection.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts